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I n this issue of the Journal, Tamburino et al. (1)have published a study that compares the clinicaloutcomes of aortic valve replacement (AVR) with
transcatheter aortic valve replacement (TAVR) at 1
year from the OBSERVANT (Observational Study of
Effectiveness of SAVR–TAVR Procedures for Severe
Aortic Stenosis Treatment) registry, which investi-
gates the management of aortic stenosis (AS) in 93
institutions in Italy. The registry had 7,618 patients
with AS (5,707 treated with AVR and 1,991 with
TAVR). The investigators excluded 2,150 patients
because of combined procedures, porcelain aortas,
“hostile thorax,” nonfemoral TAVR, and protocol
violation. A total of 4,077 AVRs and 1,391 transfemoral
TAVRs were entered into a propensity score analysis
to identify patients with similar pre-operative char-
acteristics. The investigators were able to match
650 patients from each group with very similar clin-
ical proﬁles. These 2 groups had a mean age of
80 years, 60% were women, and they had a pre-
dicted procedure-related mortality risk, which was
calculated using the logistic EuroSCORE II, of 5.1%
for AVR and 4.9% for TAVR. The primary end-
points were death from any cause and major adverse
cardiac and cerebrovascular events (MACCE) at
1 year. MACCE were deﬁned as the composite of
death from any cause, stroke, myocardial infarction,
percutaneous coronary artery intervention, and coro-
nary artery bypass surgery. Secondary endpoints
were cerebrovascular accidents, acute myocardial*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
From the Division of Cardiovascular Surgery, Peter Munk Cardiac Centre,
Toronto General Hospital, and the University of Toronto, Toronto,
Ontario, Canada. Dr. David has reported that he has no relationships
relevant to the contents of this paper to disclose.infarction, repeat hospitalization due to cardiac rea-
sons, and acute heart failure.As would be expected, because the 2 groups of
patients were similar in age, sex, and comorbidities,
there was no difference in survival or MACCE at
1 year. The effects of the procedure itself will not
be apparent until much later, when other factors,
such as aortic insufﬁciency (AI), permanent pace-
maker implantation, and primary tissue failure of the
bioprosthetic aortic valve become apparent.
There were no surprises in other endpoints, either.
The 30-day mortality rate was 3.8% for AVR and 3.2%
for TAVR (p ¼ 0.546), and the length of hospital stay
was longer for patients who had AVR (12.6 days vs. 8.8
days; p < 0.001). The mean gradients after AVR were
slightly higher than those after TAVR, but this was not
clinically signiﬁcant. The incidence of AI ($grade 2)
was lower after AVR than that after TAVR (2% vs. 9.8%;
p< 0.001), as was the need for a permanent pacemaker
(3.6% vs.15.5%; p < 0.001). There were no differences
in stroke rates (2.2% vs. 1.3%), acute myocardial
infarction (0.8% vs. 0.5%), and cardiac tamponade
(3.9% vs. 4.1%) between the 2 groups.
It can be predicted that the investigators will ﬁnd no
differences in outcomes again when they reexamine
these 2 groups of patients at 2 or 5 years. This state-
ment is based on the knowledge of the 5-year results of
the PARTNER I (Placement of Aortic Transcatheter
Valve Trial) randomized clinical trial on AVR versus
TAVR in high-risk patients (Society of Thoracic Sur-
geons [STS]-predicted mortality risk score of 11.7%.)
(2). This study showed a 5-year mortality rate of 62.4%
after AVR and amortality rate of 67.8% after TAVR (p¼
0.76) (2). Other important ﬁndings in PARTNER I
included no cases of primary tissue failure in either
group at 5 years, and as demonstrated previously (3),
AI had a detrimental effect on survival in patients who
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814had TAVR, but there was no apparent effect on overall
survival up to 5 years.
The investigators of this OBSERVANT study iden-
tiﬁed 650 TAVR patients with a relatively low opera-
tive risk score (EuroSCORE II of 4.9%) to compare
with AVR. This suggests that our Italian colleagues
are adopting TAVR as an alternative to AVR in older
patients who are at a lower operative risk than
those described in a randomized clinical trial (2).
This is not surprising, because both the Edwards
SAPIEN (Edwards Lifesciences, Irvine, California) and
the Medtronic CoreValve (Medtronic, Minneapolis,
Minnesota) devices have been approved for clinical
use in Europe since 2007, and one would expect that,
as experience with TAVR increases and more data on
favorable outcomes become available, more patients
will be offered TAVR as an alternative to AVR. This is
more evident in Germany, where an ever-increasing
number of patients with AS are being treated with
TAVR (4). In a recent report from the GARY (German
Aortic Valve Registry) study (4), a total of 15,964
patients underwent TAVR in 88 centers in Germany
from 2011 to 2013. In 2011, the proportion of isolated
AS treated with TAVR was 30%, which increased to
35% in 2012, without an increase in the total number
of treated patients (5). This occurred before the
results of randomized clinical trials in lower risk
patients (SURTAVI [Safety and Efﬁcacy Study of the
Medtronic CoreValve System in the Treatment of
Severe, Symptomatic Aortic Stenosis in Intermediate
Risk Subjects Who Need Aortic Valve Replacement]
and PARTNER II) have become available.
Registries such as OBSERVANT and GARY are very
important because they capture all patients treated
by both methods in multiple hospitals. Unlike many
other catheter-based cardiovascular interventions,
TAVR has been cautiously introduced and monitored.
The role of TAVR in the treatment of AS is likely to
continue to expand, and it may become the ﬁrst
choice of therapy if mortality and morbidity associ-
ated with the procedure and late outcomes are similar
or better than AVR. Several issues need to be resolved
before this becomes reality.
AI has a negative effect on survival after TAVR, but
no effect on overall survival, which is likely because
of sample size and duration of follow-up (2,3). The
higher rate of permanent pacemaker implantation
after TAVR than after AVR may also affect long-term
survival; further follow-up is needed. The durability
of bioprosthetic heart valves after AVR is well docu-
mented (6,7), but there is limited information on the
durability of TAVR (2). PARTNER I showed no primary
tissue degeneration up to 5 years of follow-up, but the
number of patients at risk was relatively small (2).However, this ﬁnding is encouraging and endorses
the more widespread use of TAVR. Age is the single
most important determinant of primary tissue
degeneration after AVR with bioprosthetic valves
(6,7). Because TAVR has been used largely in older
patients, age may not be as relevant. However, it will
become so when used in younger patients with a
predicted survival of >5 or 10 years. Thus, it is
imperative that registries such as OBSERVANT and
GARY continue to collect echocardiographic data on
bioprosthetic aortic valve function to determine the
durability of devices used for TAVR. We do not know
if the xenograft tissue used in TAVR devices will fail
due to cusps tearing or because of detachment from
the stent, with a consequent increase in AI, or due to
stiffening and calciﬁcation of the cusps and AS, or a
combination of these factors.
Large registries, such as the STS Database, have
allowed the development of fairly accurate operative
risk calculators for various cardiac operations and of
ASCERT (American College of Cardiology Foundation—
Society of Thoracic Surgeons Collaboration on the
Comparative Effectiveness of Revascularization
Strategies) (a long-term survival probability calculator
for isolated coronary artery bypass graft surgery)
(8). The STS risk calculator and ASCERT can be down-
loaded through the STS website (9), to estimate late
survival after coronary artery bypass graft surgery.
The OBSERVANT and GARY registries will allow par-
ticipants to develop statistical models to determine
late survival after treating patients with AS. Once
the mathematical effect of each variable that affects
survival after AVR and TAVR becomes known, physi-
cians will be better equipped to recommend 1 or the
other procedure to treat an individual patient.
Another important issue before considering TAVR
in younger patients is aortic valve pathology.
Degenerative calciﬁcation of the cusps is the most
common cause of AS in patients >65 years of age, but
a bicuspid aortic valve is the most common ﬁnding in
younger patients (6). TAVR has been used in selected
patients with AS due to bicuspid aortic disease (10),
but because of the great variability in pathology of the
cusps and root, much more information is needed
before its widespread use.
Finally, I commend Tamburino et al. (1) for their
efforts in prospectively collecting the OBSERVANT
registry data, carefully analyzing the 1-year out-
comes, and sharing them with us.
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